Havens Advisors LLC purchased a new position in shares of Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSE:CTH) during the third quarter, according to its most recent filing with the SEC. The institutional investor purchased 47,500 shares of the company’s stock, valued at approximately $1,911,000. Cynapsus Therapeutics accounts for approximately 1.5% of Havens Advisors LLC’s portfolio, making the stock its 19th largest position. Havens Advisors LLC owned about 0.38% of Cynapsus Therapeutics at the end of the most recent quarter.

Institutional Ownership by Quarter for Cynapsus Therapeutics (NASDAQ:CYNA)

COPYRIGHT VIOLATION NOTICE: “Havens Advisors LLC Acquires New Stake in Cynapsus Therapeutics Inc. (CYNA)” was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/11/28/havens-advisors-llc-acquires-new-stake-in-cynapsus-therapeutics-inc-cyna.html.

A number of research analysts recently commented on the stock. Janney Montgomery Scott downgraded shares of Cynapsus Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, September 1st. Noble Financial reaffirmed a “buy” rating and issued a $50.00 price target on shares of Cynapsus Therapeutics in a report on Tuesday, August 30th. Finally, BMO Capital Markets set a $30.00 price target on shares of Cynapsus Therapeutics and gave the company a “buy” rating in a report on Tuesday, August 16th.

Cynapsus Therapeutics Company Profile

Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.

5 Day Chart for NASDAQ:CYNA

Receive News & Stock Ratings for Cynapsus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynapsus Therapeutics Inc. and related stocks with our FREE daily email newsletter.